(Total Views: 138)
Posted On: 03/19/2024 11:14:05 AM
Post# of 85338
$NBIO - announced today a collaboration to develop an alternative delivery mechanism for patients who can benefit from Pritumumab ("PTB"
, Nascent's lead monoclonal antibody cancer treatment asset, which is now in Phase II clinical research for the treatment of Brain Cancer.
https://finance.yahoo.com/news/nascent-collab...00958.html
, Nascent's lead monoclonal antibody cancer treatment asset, which is now in Phase II clinical research for the treatment of Brain Cancer. https://finance.yahoo.com/news/nascent-collab...00958.html
(0)
(0)Scroll down for more posts ▼
